

Oxurion Ends R&D Program in Geographic Atrophy and Refocuses on New CRO Activities

Leuven, BELGIUM – August 7, 2025 – 06:00 PM CET - [Oxurion NV](#) (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced the definitive termination of its preclinical research program aimed at developing new therapeutic targets for geographic atrophy (GA).

This program relied on a high-throughput genetic screening platform using CRISPR technology to identify innovative multi-target pathways beyond the complement system in the treatment of GA. Oxurion has decided to end this work in order to concentrate its resources on developing its Contract Research Organization (CRO) activities, following the acquisition of Axiodis CRO in the summer of 2025.

This strategic decision enables a rationalization of internal resources, cessation of R&D-related expenses, and an increased focus on revenue-generating activities. It is part of Oxurion’s transformation toward a business model focused on profitability and targeted external growth.

In this context, the company is actively exploring complementary acquisition opportunities, with the goal of building a profitable and integrated group centered around clinical data. Oxurion specifies that only profitable companies with differentiated expertise and strong growth potential will be considered under this selective strategy. Several strategic targets in Europe are currently under evaluation or being approached.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group’s headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Additional Disclaimer

The planned investment in digital assets (such as Bitcoin and Ethereum) exposes the company to specific risks related to volatility, regulatory uncertainty, and cybersecurity. These factors may significantly affect the expected performance of the investments.

For further information please contact:

<p>Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com</p>
--